US OptionsDetailed Quotes

PRLD240816C7500

Watchlist

0.25
0.000.00%

15min DelayClose Jul 23 13:23 ET

0.00High0.00Low

Prelude Therapeutics Stock Discussion

Stock Region

Jul 10 10:17

Therapeutics Company Announces Major Clinical Collaboration With Merck

Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.
On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 t...

Update

NEWS

$Prelude Therapeutics (PRLD.US)$
Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate the combination of Prelude's PRT3789, a selective SMARCA2 degrader, with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with SMARCA4-mutated cancers. The Phase 2 clinical study aims to explore the potential ...

Mr Long Term

Jun 22 21:57

Columns Wall Street's Top 10 Call This Week.

Wall Street experts reveal the five stocks to buy, five stocks to sell this week
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
Top 5 Buy Calls:
1. Skyworks upgraded to Buy at B. Riley
$Skyworks Solutions (SWKS.US)$
B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...

Moomoo AI

Dec 11, 2023 08:37

Prelude's CEO, Dr. Kris Vaddi, asserts that the additional funding will boost the clinical development of PRT3789 and progress of the oral program. Further clinical results from PRT3789 and the initiation of their oral program are expected in second half of 2024.

Press Release: Prelude Therapeutics Announces $25 Million Private Placement

Moomoo AI

Nov 7, 2023 04:31

The stock has a high risk of funding distress due to high cash expenditure relative to the company's market value. Increasing cash burn trajectory may require further capital raising, risking shareholder value dilution.

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Trytosaveabit

Nov 1, 2023 16:56

Better earnings

$Prelude Therapeutics (PRLD.US)$ Prelude Therapeutics Q3 EPS $(0.45) Beats $(0.58) Estimate

Trytosaveabit

Nov 1, 2023 15:11

Update

$Prelude Therapeutics (PRLD.US)$ Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Analysts Notebook

Mar 15, 2022 06:27

Columns Top upgrades and downgrades on 3/15

Upgrades
• $Ascendis Pharma A/S (ASND.US)$: BofA Securities Upgrades to Buy from Neutral - PT $161 (from $148)
• $GoodRx (GDRX.US)$: Baird Upgrades to Outperform from Neutral - PT $17
• $W.W. Grainger (GWW.US)$: Atlantic Equities Upgrades to Overweight from Neutral - PT $580 (from $520)
• $Heartland Express (HTLD.US)$: Morgan Stanley Upgrades to Equalweight from Underweight - PT $16
• $The Mosaic (MOS.US)$: Goldman Sachs Upgrades to Buy from Neutral - PT $83
• $Northern Oil & Gas (NOG.US)$: Johnson ...

starskymoon

Oct 10, 2021 23:06

$Prelude Therapeutics (PRLD.US)$ @Tupack H McsnacksGood afternoon..just started investing, may I know to hold or exit for PRLD which has been heading downwards, your advice is deeply appreciated. Thanks

No comment yet